1.49
1.49 (0%)
As of Feb 14, 2025
Werewolf Therapeutics, Inc. [HOWL]
Source:
Company Overview
Werewolf Therapeutics, Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies.
| Country | United States |
| Headquarters | watertown, massachusetts |
| Phone Number | 617-952-0555 |
| Industry | |
| CEO | Daniel J. Hicklin |
| Website | www.werewolftx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $1.9 |
| Operating Profit | $-73.6 |
| Net Income | $-70.5 |
| Net Cash | $-43.4 |
Profit Ratios
| Gross Margin | $1.9 |
| Operating Margin | -3,904.2 |
| Profit as % of Revenues | -2.7% |
| Profit as % of Assets | -46.7% |
| Profit as % of Stockholder Equity | -96.1% |
Management Effectiveness
| Return on Equity | -96.1% |
| Return on Assets | -55.6% |
| Turnover Ratio | 1.3% |
| EBITA | $-73.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $126.9 |
| Total Liabilities | $53.5 |
| Operating Cash Flow | $-56.2 |
| Investing Cash Flow | $-0.3 |
| Financing Cash Flow | $13.1 |
